Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating UCB0022 in advanced Parkinson's disease has completed, with data assessing efficacy, safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• UCB0022

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED